MedTrace Logo

A Clinical Trial of Infliximab for Uveitis

NCT00273390 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2011-07-04

No results posted yet for this study

Summary

This project is designed to test the hypothesis that inhibition of binding between tumor necrosis factor alpha (TNF-alpha) and its receptors using Remicade (infliximab, chimeric mouse/human IgG1K monoclonal antibody directed against human TNF-alpha, Centocor, Malvern,PA) is clinically useful for patients with uveitis that is refractory to other forms of systemic immunosuppressive therapy.

Conditions

  • Uveitis

Interventions

DRUG

Remicade (infliximab)

Sponsors & Collaborators

  • Centocor, Inc.

    collaborator INDUSTRY

  • Oregon Health and Science University

    lead OTHER

Principal Investigators

  • James T Rosenbaum, MD · Oregon Health and Science University

  • Eric B Suhler, MD · Oregon Health and Science University

  • Justine Smith, MBBS, Phd · Oregon Health and Science University

Eligibility

Min Age
9 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-08-31
Primary Completion
2006-12-31
Completion
2006-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00273390 on ClinicalTrials.gov